Live Webinar

Protein expression remains a critical bottleneck in the journey of biotherapeutic development, spanning from initial discovery to lead optimization and beyond. The prolonged timelines associated with cell-line development exacerbate this challenge, necessitating the exploration of novel technologies for expediting the process.

In this 30-minute webinar, LenioBio’s Chief Scientific Officer, Dr. Ricarda Finnern, will delve into the transformative potential of a next generation cell-free protein expression platform in overcoming these hurdles. Through case studies, attendees will gain a comprehensive understanding of how this innovative system accelerates the development of vaccines and biotherapeutics, including detailed insights into a rapid high-throughput screening protocol. Ricarda will also share first in-animal pharmacokinetics data obtained with a therapeutic antibody, offering valuable insights into the quality and safety profile of proteins produced using the platform.

Join us as we embark on a journey to revolutionize biotherapeutic development, leveraging cutting-edge technology to overcome traditional limitations and expedite the translation of scientific discoveries into tangible medical solutions.

Dr. Ricarda Finnern

Ricarda, Chief Scientific Officer at LenioBio, joined the company in 2019 from Bayer AG, where she was leading several global development programs for biologics and small molecules in oncology and cardiovascular and nephrological indications.

Ricarda is a molecular biologist and immunologist by training and has over 25 years of experience in academia, contract research organizations, and the pharmaceutical industry.

At LenioBio, she heads a team of innovators tasked with pushing the boundaries of cell-free expression to support biotherapeutic development and manufacture.

24-01-12_LenioBio_1_3512_sRGB-1920w-aspect-ratio-250-180

The ALiCE® Technology

ALiCE® is a eukaryotic cell-free protein expression harnessing the power of N. tabacum cells.

24-01-12_LenioBio_1_4133_sRGB-1920w-aspect-ratio-250-180

ALiCE® as a Service

Leverage our team's expertise for your protein expression project with our end-to-end protein service.

24-01-12_LenioBio_1_3763-1920w-aspect-ratio-250-180

Scaled Protein Producton With ALiCE®

ALiCE® is the first fully scalable eukaryotic cell-free system. Learn about seamless scalability from microgram to milligram.

No results